abstract |
Novel compounds of Formula I are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHSO 2 R, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n 1 and n 2 are independently selected from 0, 1, and 2. At least one of R 3 and R 4 and/or R 5 and R 6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO 2 . Additionally, when R 3 and R 4 or R 5 and R 6 do not form a cyclic ring, then they may be independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L 1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms. The chain may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R 2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR 7 , wherein R 7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', NHSO2R, or NHCOR. Y 1 is oxygen or hydrogen. Y 2 is optional, wherein when Y2 is present, Y 1 and Y 2 are hydrogen. When Y 2 is not present, Y 1 is a carbonyl group. |